CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodi... (was conducted in 28 centers in Brazil Ca...)

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

Date:5/14/2008

was conducted in 28 centers in Brazil, Canada and the U.S. and evaluated the efficacy, safety and immunogenicity of GSK's candidate vaccine for the prevention of infection with cancer causing virus types 16 and/or 18, and other cancer-causing virus types, as well as prevention of associated Pap smear abnormalities and cervical precancerous lesions. In the extended follow-up study, women were evaluated for the presence of human papillomavirus DNA by PCR using cervical samples and annual cervical cytology evaluations were performed. Women were referred for colposcopy following protocol guidelines. Women were also assessed for long-term immunogenicity and safety.

About cervical cancer and its progression

Approximately 100 types of human papillomavirus have been identified to date and, of these, approximately 15 virus types are known to cause cervical cancer. Virus types 16, 18, 45 and 31 are responsible for approximately 80 percent of cervical cancers globally. Persistent infection with cancer-causing virus types can lead to the formation of abnormal cells in the cervix, which, over time, may become precancerous or cancerous. Human papillomavirus is a necessary precursor of cervical cancer. Throughout their lifetime, women may be exposed to cancer-causing virus types and are potentially at risk of developing cervical cancer.

Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and over 280,000 women will die from it each year.

About the GSK Cervical Cancer Vaccine

To date, CERVARIX(R) has been approved in more than 60 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in more than 35 additional countries including Japan. GSK also submitted CERVARIX(R) to the World Health Organization (WHO) for prequalification in September 2007.

GSK submitted a Biologics License Application (BL
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
9. Raptor Pharmaceuticals Provides Update of Product Programs
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial

Post Your Comments:

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodi...(was conducted in 28 centers in Brazil Ca...),Health